S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
NASDAQ:MNOV

MediciNova (MNOV) Stock Forecast, Price & News

$2.10
-0.03 (-1.41%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.07
▼
$2.10
50-Day Range
$2.01
▼
$2.51
52-Week Range
$1.89
▼
$2.73
Volume
23,225 shs
Average Volume
18,893 shs
Market Capitalization
$103.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

MediciNova MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
0.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of MediciNova in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.33) to ($0.34) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.61 out of 5 stars

Medical Sector

962nd out of 963 stocks

Pharmaceutical Preparations Industry

449th out of 450 stocks

See Top Rated MarketRank™ Stocks Here

MNOV stock logo

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

MNOV Price History

MNOV Stock News Headlines

September 26, 2023 | americanbankingnews.com
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com
September 26, 2023 | americanbankingnews.com
MediciNova (NASDAQ:MNOV) Stock Price Passes Above 200 Day Moving Average of $2.25
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 18, 2023 | americanbankingnews.com
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com
August 21, 2023 | finance.yahoo.com
MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury…
August 17, 2023 | finance.yahoo.com
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
August 16, 2023 | benzinga.com
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
August 16, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 16, 2023 | msn.com
Medicinova (NASDAQ:MNOV) Rises on Key Patent Win in Europe
August 15, 2023 | finance.yahoo.com
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
August 14, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
July 23, 2023 | finance.yahoo.com
With 49% ownership, MediciNova, Inc. (NASDAQ:MNOV) has piqued the interest of institutional investors
June 29, 2023 | msn.com
Traders Cheer After Bank Stress Test Results, Lifting US Equity Futures
June 29, 2023 | finance.yahoo.com
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
May 30, 2023 | finance.yahoo.com
MNOV: Compelling Buying Opportunity in Differentiated Small-Cap Biotech
May 15, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
May 14, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
April 30, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
April 15, 2023 | finance.yahoo.com
MediciNova, Inc. (MNOV) Stock Historical Prices & Data - Yahoo Finance
March 31, 2023 | nasdaq.com
Medicinova Inc Common Stock (MNOV)
March 9, 2023 | finance.yahoo.com
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
February 27, 2023 | finance.yahoo.com
MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled…
February 20, 2023 | finance.yahoo.com
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
February 8, 2023 | finance.yahoo.com
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
January 30, 2023 | finance.yahoo.com
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
January 12, 2023 | finance.yahoo.com
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
See More Headlines
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings
8/09/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNOV
CUSIP
N/A
CIK
1226616
Web
medicinova.com
Phone
(858) 373-1500
Fax
858-404-0048
Employees
13
Year Founded
2000

Profitability

EPS (Most Recent Fiscal Year)
($0.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,060,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-18.02%
Return on Assets
-17.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.97
Quick Ratio
18.97

Sales & Book Value

Annual Sales
$4.04 million
Price / Sales
25.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.43 per share
Price / Book
1.47

Miscellaneous

Outstanding Shares
49,046,000
Free Float
40,757,000
Market Cap
$103.00 million
Optionable
Optionable
Beta
0.93

Social Links

20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Yuichi Iwaki M.D. (Age 73)
    Ph.D., Co-Founder, Pres, CEO & Exec. Director
    Comp: $933.05k
  • Dr. Kazuko Matsuda M.D. (Age 57)
    M.P.H., MPH, Ph.D., Chief Medical Officer & Director
    Comp: $653.65k
  • Mr. Jason J. Kruger CPA (Age 46)
    CFO & Principal Financial Officer
  • Dr. David H. Crean M.B.A. (Age 58)
    Ph.D., Chief Bus. Officer
  • Mr. John O'Neil CPA
    Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings or view top-rated stocks.

How have MNOV shares performed in 2023?

MediciNova's stock was trading at $2.05 at the start of the year. Since then, MNOV stock has increased by 2.4% and is now trading at $2.10.
View the best growth stocks for 2023 here.

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our MNOV earnings forecast.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01.

What other stocks do shareholders of MediciNova own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY).

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a number of institutional and retail investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (38.02%), BlackRock Inc. (1.49%), Citigroup Inc. (1.02%), JPMorgan Chase & Co. (0.34%), Bank of Montreal Can (0.26%) and Dimensional Fund Advisors LP (0.23%).
View institutional ownership trends.

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $2.10.

How much money does MediciNova make?

MediciNova (NASDAQ:MNOV) has a market capitalization of $103.00 million and generates $4.04 million in revenue each year. The biopharmaceutical company earns $-14,060,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -